Dodge & Balanced is managed by a capable and experienced team that continues to evolve this strategy’s investment approach to better investor outcomes. The strategy is guided by the Dodge & Cox Fund Investment Committee, which was created in May 2022 and brings together senior equity, fixed-income, and quantitative investors, all of whom invest more than USD 1 million in the fund. That alignment strengthens shareholder interests, while the committee benefits from broad input through bottom-up equity research, credit analysis, and quantitative oversight. Still, most security-selection and risk-sizing decisions remain largely within the underlying equity and fixed-income sleeves, limiting the committee's role as a truly integrated multi-asset allocator.
Dodge & Cox Balanced Fund Class X DOXBX
- NAV / 1-Day Return 14.21 / −0.42 %
- Total Assets 15.1B
-
Adj. Expense Ratio
0.420%
- Expense Ratio 0.410%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Moderate Allocation
- Investment Style Large Value
- Credit Quality / Interest Rate Sensitivity Medium/Moderate
- Status Open
- TTM Yield 2.29%
- Turnover 30%
USD | NAV as of Sep 05, 2026 | 1-Day Return as of Sep 05, 2026, 9:52 AM GMT+0
Morningstar’s Analysis DOXBX
Will DOXBX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 16.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
CVS Health Corp | 2.29 | 336M | Healthcare |
Taiwan Semiconductor Manufacturing Co Ltd | 2.20 | 322M | Technology |
Dodge & Cox Emerging Markets Stock | 2.19 | 321M | — |
Charles Schwab Corp | 2.10 | 308M | Financial Services |
Humana Inc | 1.57 | 230M | Healthcare |
Alphabet Inc Class C | 1.54 | 225M | Communication Services |
RTX Corp | 1.39 | 204M | Industrials |
Fixed Income Clearing Corporation Repurchase Agreement | 1.29 | 189M | Cash and Equivalents |
GSK PLC ADR | 1.23 | 181M | Healthcare |
Microsoft Corp | 1.21 | 177M | Technology |